
|Articles|April 17, 2006
Advances in treatment of MI reported at ACC show
The low molecular weight heparin enoxaparin (Lovenox, Sanofi-Aventis) is superior to unfractionated heparin as an adjunct to thrombolytic therapy in patients with ST elevation myocardial infarction (MI), researchers reported at the 55th Annual Scientific Session of the American College of Cardiology (ACC). The meeting was held in Atlanta last month.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
New Study Finds Compounded GLP-1s Remain Robust Despite End of Shortages
2
ICER Report Finds GLP-1s Are Cost-Effective But Warns of Budget Strain
3
Once Weekly Oral HIV Regimen Maintains Suppression Through Week 48
4
Postpartum Mothers Favor Bedtime Stopping Rule Over Stricter Chrononutrition Approaches
5






























